Latest revenue
$1.50B
as of 2025-12-31
Latest net income
$192.9M
as of 2025-12-31
Net margin
12.9%
as of 2025-12-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $21.24B
- Enterprise value
- $22.71B
- P/E (trailing)
- 34.6×
- Forward P/E
- —
- P/B
- 2.97×
- Dividend yield
- 1.1%
- 52-wk high
- $269.44
- 52-wk low
- $195.14
- Beta
- —
- Shares out
- 98.1M
5-year trend
dashed bar = fiscal Q4 derived from 10-K annual − Q1 − Q2 − Q3 (SEC requires only three 10-Qs per year).
What this company does
STERIS sells infection-prevention and sterilization products and services to hospitals, medical device makers, and pharmaceutical labs, including sterilizers, surgical tables, detergents, scope repair, and contract sterilization of medical devices. Revenue splits roughly evenly between product sales ($2.21B) and recurring service work ($2.13B) across three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. Following the Dental divestiture, STERIS now operates as a focused three-segment business, with nine-month revenue up 9% and operating income up 21% as margin expansion takes hold.
Generated from STE's filing dated 2025-05-29
Key risks
- Heavy intangibles exposure: $4.23B goodwill plus $1.69B intangibles equal 56% of total assets, leaving substantial impairment risk if growth slows.
- Leverage remains elevated: $1.90B long-term debt against $423.7M cash; nine-month interest expense of $45.6M pressures earnings if rates stay high.
- FX volatility material: cumulative translation swung $249.6M favorably in nine months after a $45.5M loss prior year, driving comprehensive income variability.
Generated from STE's filing dated 2025-05-29
Profitability
Gross margin
44.0%
2.0%Operating margin
15.9%
2.4%Net margin
11.3%
53.0%Return on equity
9.3%
55.1%Return on assets
6.1%
77.2%Leverage
Debt / equity
0.54×
29.0%Long-term debt / equity
0.29×
41.3%Debt / assets
34.9%
18.9%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q4 2025 2025-12-31 | $1.50B | +9.2% | $192.9M | +11.2% | 12.9% |
Q3 2025 2025-09-30 | $1.46B | +9.9% | $191.9M | +27.9% | 13.1% |
Q2 2025 2025-06-30 | $1.39B | +8.7% | $177.4M | +22.0% | 12.8% |
Q1 2025 2025-03-31 | $1.48B | +4.3% | $145.7M | +10684.0% | 9.8% |
Q4 2024 2024-12-31 | $1.37B | +5.6% | $173.5M | +23.3% | 12.7% |
Q3 2024 2024-09-30 | $1.33B | +7.3% | $150.0M | +30.1% | 11.3% |
Q2 2024 2024-06-30 | $1.28B | +8.1% | $145.4M | +17.7% | 11.4% |
Q1 2024 2024-03-31 | $1.42B | — | $-1.4M | — | -0.1% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Orthopedic, Prosthetic & Surgical Appliances & Supplies · SIC 3842
Your notes
Keep private notes on STE — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$16.7M
Net activity
−$16.7M
Distinct insiders
7
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns STE
Institutional value
$10.22B
Total shares held
48.6M
Distinct holders
594
As of
2026-03-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 9.0M | $2.00B | — | New |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 6.4M | $1.41B | — | New |
| 3 | VANGUARD PORTFOLIO MANAGEMENT LLC | 5.0M | $1.09B | — | New |
| 4 | Mitsubishi UFJ Asset Management Co., Ltd. | 2.2M | $485.4M | — | New |
| 5 | Invesco Ltd. | 1.7M | $377.8M | — | New |
| 6 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1.3M | $277.2M | — | New |
| 7 | FRANKLIN RESOURCES INC | 1.2M | $274.8M | — | New |
| 8 | DIMENSIONAL FUND ADVISORS LP | 1.1M | $246.3M | — | New |
| 9 | PRINCIPAL FINANCIAL GROUP INC | 890.6K | $196.9M | — | New |
| 10 | Boston Partners | 862.3K | $190.7M | — | New |
| 11 | Pictet Asset Management Holding SA | 823.6K | $182.1M | — | New |
| 12 | Legal & General Group Plc | 764.4K | $169.0M | — | New |
| 13 | Findlay Park Partners LLP | 674.8K | $149.2M | — | New |
| 14 | DEUTSCHE BANK AG\ | 583.1K | $128.9M | — | New |
| 15 | ROYAL LONDON ASSET MANAGEMENT LTD | 556.9K | $123.2M | — | New |
| 16 | VANGUARD FIDUCIARY TRUST CO | 552.0K | $122.1M | — | New |
| 17 | Sustainable Growth Advisers, LP | 547.2K | $121.0M | — | New |
| 18 | UBS Group AG | 546.9K | $120.9M | — | New |
| 19 | Bank of New York Mellon Corp | 524.5K | $116.0M | — | New |
| 20 | JPMORGAN CHASE & CO | 443.5K | $97.3M | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
- 1
Inventories jumped $92M to $673.5M while revenue grew only 9%—is this tariff pre-buying, channel stuffing, or softening AST demand we should worry about?
- 2
Service gross margin compressed to 41.1% from 40.4% YoY—what's driving cost growth outpacing the 10% service revenue gain, and when does this inflect?
- 3
With $423.7M cash and only $20.1M spent on M&A YTD versus $161M buybacks, has the Healthcare deal pipeline dried up post-Cantel integration?
Refreshed when STE files a new report · last from 2025-05-29